Document:

EX-10.64

 Exhibit 10.64 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT NO. TWO 
 TO

 LICENSE AGREEMENT 

THIS AMENDMENT NUMBER TWO TO LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective January 15,
1999, by and between Genentech, Inc. (“Genentech”) and Connetics Corporation (“Connetics”). 
 R E
C I T A L S 
  

	A.	The Parties have previously entered into that certain License Agreement for Interferon Gamma, dated May 5, 1998, as amended on December 23, 1998 (the “License Agreement”). 

 

	B.	Pursuant to Section 2.3(c) of the License Agreement, Connetics has the right to sublicense certain of its rights under the Agreement to InterMune Pharmaceutical, Inc. (“InterMune”), and has in fact
entered into a sublicense to that effect dated August 21, 1998 

  

	C.	On December 3, 1998, the Parties entered into a Letter Agreement to document the intent and agreement of Connetics and Genentech with respect to additional terms governing the transfer and distribution of
Interferon Gamma-1B, pending the preparation of an amendment to the License Agreement. 

  

	D.	The Parties now desire to enter into a definitive amendment to the License Agreement, effective as of the date first written above, to permit a limited distribution of Interferon Gamma-1B by Connetics or its sublicensee
under Genentech labels and to add other additional terms governing the transfer and distribution of Interferon Gamma-1B. 

 NOW THEREFORE, the
Parties hereby agree as follows: 
 AGREEMENT 
  

	1.	Terms not otherwise defined in this Amendment shall have the meanings defined in the License Agreement. 

  

	2.	Section 1.29 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

1.29 “Transfer Date” shall mean January 15, 1999, unless otherwise mutually agreed to in writing by the Parties. 

	3.	A new Section 1.30 is added to the License Agreement to read in its entirety as follows: 

1.30 “Connetics Product” shall mean Finished Product under the ACTIMMUNE®
trademark and labeled under the name of Connetics or its sublicensee. For clarification, all terms and conditions of this Agreement that apply to Finished Product shall also apply to Connetics Product. 

 

	4.	A new Section 1.31 is added to the License Agreement to read in its entirety as follows: 

1.31 “Distribution Period” shall mean the period of time beginning January 15, 1999 and ending on the earlier of: (a) the
first date on which Genentech supplies InterMune with Connetics Product or (b) sixty (60) days after InterMune’s receipt of a license from the FDA to sell Interferon Gamma-1B for CGD. 

 

	5.	A new Section 1.32 is added to the License Agreement to read in its entirety as follows: 

1.32 “Genentech Finished Product” shall mean Genentech’s inventory of Interferon Gamma-1B under the ACTIMMUNE® trademark and labeled under Genentech’s name. For clarification, Genentech Finished Product is a Licensed Product under this Agreement. 

 

	6.	A new Section 1.33 is added to the License Agreement to read in its entirety as follows: 

1.33 “Genentech Bulk Product” shall mean Genentech’s inventory of Interferon Gamma-1B bulk protein existing as of the Transfer
Date. 
  

	7.	A new Section 1.34 is added to the License Agreement to read in its entirety as follows: 

1.34 “Genentech Product” shall mean, together, Genentech Finished Product and Genentech Bulk Product. 

 

	8.	A new Section 1.35 is added to the License Agreement to read in its entirety as follows: 

1.35 “Fully Burdened Manufacturing Cost” shall mean ***
                                         
                           
                                
                            , which shall be comprised of the sum of: ***
                                         
                            
                        
                            
                                         
                                        
                                         
                                    

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

2 

 
                                
                                         
                               
                            
                                
                        
                         
                                
                                         
                                         
                      
                        
                                
                                         
                                   
                                         
                                    
                                    
                                        
                                         
                                    
                             . 
  

	9.	A new Section 1.36 is added to the License Agreement to read in its entirety as follows: 

1.36 “Third Party Manufacturing Royalties” shall mean all royalties paid or incurred by Genentech to third parties
under licenses taken by Genentech with respect to patents or patent applications that, but for such license(s), would be infringed by the manufacture, use, sale, offer for sale or importation of Genentech Finished Product or Genentech Bulk Product,
which royalties are based on the manufacture and sale of Genentech Finished Product or Genentech Bulk Product by Genentech (or its contract manufacturer) or by Connetics or its sublicensees (or a contract manufacturer on their behalf). Genentech
shall notify Connetics in writing during the term of this Agreement if it becomes aware of any Third Party Manufacturing Royalties. 
  

	10.	A new Subsection 2.5(k) is added to the License Agreement to read in its entirety as follows: 

2.5(k) Provided that all the activities listed on Exhibit H attached hereto are completed, Genentech also shall transfer to
Connetics or its sublicensee on the Transfer Date all responsibility for the distribution, sales and product support of Genentech Finished Product, in the Territory, for the treatment of infections associated with CGD, subject to the provisions of
Section 4.3 below and the following terms and conditions: 
 (i) Product support of Genentech Finished Product shall
include, without limitation, all financial services, all reporting required by federal and state law or regulation, professional services, customer inquiries, product returns, government chargebacks, product refunds, and patient assistance programs,
except for the processing of state Medicaid invoices and certain product returns, as provided in Subsections 2.5(k)(iii) and (iv) below. 

(ii) Connetics or its sublicensee shall sell and distribute Genentech Finished Product only during the Distribution Period,
after which time Connetics or its sublicensee shall market, sell and distribute Connetics Product, or other Finished Product, for CGD. Notwithstanding the foregoing, for a period of ten (10) business days after the last day of the Distribution
Period, Connetics or its sublicensee may continue to sell and distribute its existing inventory of Genentech Finished Product in order to reduce or exhaust 

  
 3 

 
such existing inventory. Under no circumstances, however, will Genentech be required to manufacture, fill, label, package, or otherwise supply Genentech Finished Product to Connetics or its
sublicensees after the end of the Distribution Period. After the Distribution Period Connetics or its sublicensees shall retain full responsibility, and provide all product support, for all Genentech Product sold or distributed by Genentech,
Connetics or its sublicensees, prior to, during and after the Distribution Period, including without limitation, Genentech Product in distribution channels. 

(iii) Notwithstanding the above, Genentech shall remain responsible for processing state Medicaid invoices for Genentech
Finished Product, in accordance with this subsection, during the Distribution Period and for that period of time after the Distribution Period during which states continue to send Medicaid rebate invoices for Genentech Finished Product sold under
the Genentech NDC label number 50242. Within fifteen (15) days after the end of each calendar quarter, Connetics or its sublicensee shall supply Genentech with a report of its Average Manufacturer Price (“AMP”) and Best Price
(“BP”), as defined in the U.S. Omnibus Budget Reconciliation Act of 1990 (“OBRA 90”), for Genentech Finished Product for such quarter, and detailed calculations determining such AMP and BP. The AMP, BP and supporting calculations
shall be based on the carton price for Genentech Finished Product. Genentech shall report such quarterly AMP and BP to the Health Care Finance Administration as required by law and regulation, and will also process state Medicaid rebate invoices
received for Genentech Finished Product. Genentech will pay, adjust or dispute the state Medicaid rebate invoices as permitted under OBRA 90. Within sixty (60) days of receipt of an invoice from Genentech, Connetics or its sublicensee will
reimburse Genentech the full amounts of Medicaid rebates paid by Genentech. Genentech will have the right to examine, but not more than once every calendar year, the books of account and records of Connetics and its sublicensees for the purpose of
determining the correctness of the quarterly reports provided by Connetics or its sublicensees under this subsection. If Genentech reasonably determines that any such reports(s) were incorrect, Connetics shall pay Genentech’s costs of
correcting its reports to federal agencies and will also pay any penalties or fees associated with such incorrect reporting. 

(iv) As of the Transfer Date, Connetics or its sublicensees will be; responsible for processing returns and related credits for
all Finished Product, except that Genentech will process credits for returns of Genentech Finished Product if Genentech receives a returned Genentech Finished Product from a third party. Within sixty (60) days of receipt of an invoice from
Genentech, Connetics or its sublicensees will reimburse Genentech for such return credits processed by Genentech. 

  
 4 

 (v) Connetics or its sublicensees shall be responsible for all government
chargebacks for Genentech Finished Product sold by wholesalers to customers on and after the Transfer Date, and for all government chargebacks for all Connetics Product and other Finished Product sold by Connetics and its sublicensees. 

(vi) Connetics and its sublicensees shall not actively market or promote Interferon Gamma-1B during the Distribution Period and
while selling or distributing Genentech Finished Product. During the Distribution Period, Connetics and its sublicensees shall not distribute any notice, publication or make any presentation to any third party regarding Interferon Gamma-1B without
Genenetch’s prior review of such notice, publication or presentation, and receipt of Genentech’s prior written consent. Connetics and its sublicensees shall not sell Genentech Finished Product at a price higher than that charged by
Genentech on January 14, 1999. 
  

	11.	A new Section 2.5(l) is added to the License Agreement to read in its entirety as follows: 

2.5(l) Connetics agrees that, as of the Transfer Date and under the terms and conditions below, it or its sublicensee will
supply Genentech Finished Product to those certain patients in the U.S. to whom Genentech has an existing contractual or regulatory obligation to supply Interferon Gamma-1B, including prior clinical study patients. In addition, Connetics or its
sublicensee will supply Genentech Finished Product to Hoffman-LaRoche Canada Limited (“Roche Canada”) for distribution to patients to whom there is a contractual or regulatory obligation to supply Interferon Gamma-1B. Connetics also agrees
that it or its sublicensee will supply Genentech Finished Product free of charge to those ***     oncology study patients (including ***   National Cancer Institute oncology clinical trial patients) who are continuing
to receive Interferon Gamma-1B. Genentech shall supply a list of all such patients, and information regarding the amount and destination of such Interferon Gamma-1B, as soon as reasonably possible. After the end of the Distribution Period, Connetics
or its sublicensee shall supply Connetics Product, or other Finished Product, to such patients and to Roche Canada in the same quantities. No other right or license is implied or granted to Connetics or its sublicensees to distribute Genentech
Finished Product, or any other Licensed Product, outside the Field of Use or outside the Territory. 
 (i) To supply the
patients and Roche Canada as described above, Connetics or its sublicensee shall pay a price for such Genentech Finished Product, and such Connetics Product and other Finished Product supplied by Genentech, equal to
***             percent (*** ) of Genentech’s Fully Burdened Manufacturing Cost, plus ***     of Third Party Manufacturing

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

5 

 
Royalties attributable to the manufacture or distribution of such Genentech Finished Product or other Finished Product. 

(ii) For U.S. CGD clinical study patients that do not qualify for Connetics’ (or its sublicensee’s) indigent patient
program, Connetics (or its sublicensee) shall supply, at its own cost, Genentech Finished Product and Finished Product to such patients free of charge for a period of time ending not later than December 31, 1999. Connetics (or its sublicensee)
shall notify such patients that such drug shall not continue to be supplied free of charge by Genentech, Connetics or its sublicensee, and Connetics or its sublicensee shall use its best efforts to terminate such supply of drug before
December 31, 1999, after reasonable prior notice to such patients. ***
                                         
                                         
                                       
                                         
                                         
          
                                         
                               
                                         
                                         
          
                                         
                                         
                   
                        
                                         
                                         
                                         
                             
                
                                         
       
                                         
                                 
                                         
   . 
 (iii) Roche Canada will reimburse Connetics, or its sublicensee, for its cost of supplying such
Genentech Finished Product and Connetics Product to the patients in Canada under a separate agreement to be negotiated and executed by Roche Canada and Connetics. 

(iv) Connetics, or its sublicensee, will supply Genentech Finished Product and Finished Product to the
***     oncology patients without charge to Genentech or to such patients. If, however, Genentech has not extended the Field of Use of this Agreement to the field of oncology within six (6) months of the Effective Date of
this Amendment No. 2, then Genentech will reimburse Connetics, or its sublicensee, for the cost of such Genentech Finished Product and Finished Product during such six month period. If Genentech thereafter extends the Field of Use to oncology,
then as of the effective date of such extension Connetics or its sublicensee will provide Finished Product to such patients without charge to Genentech or to such patients. If Genentech does not extend the Field of Use to oncology, Connetics or its
sublicensee will continue to supply such oncology patients, but Genentech will reimburse Connetics, or its sublicensee, for such drug in an amount equal to one hundred percent (100%) of the price paid to Genentech for such Genentech Finished
Product and Finished Product and the direct administrative and distribution costs of providing such drug to such patients. 
  

	12.	A new Section 4.3 is added to the License Agreement to read in its entirety as follows: 

4.3(a) Genentech shall sell to Connetics, or its sublicensee, Genentech’s existing inventory of Genentech Product for
commercial sale 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

6 

 
solely for the treatment of infections associated with CGD. Connetics shall pay a price for such Genentech Product equal to
***                 percent (***   ) of Genentech’s Fully Burdened Manufacturing Cost, plus ***   of Third Party Manufacturing Royalties
attributable to the manufacture or sale of such Genentech Product. 
 (b) Genentech shall deliver Genentech Finished Product
to Connetics to a single destination in the United States chosen by Connetics, by carrier identified by Connetics. Title and risk of loss as to all Genentech Finished Product shall pass to Connetics at point of origin (FOB Genentech). Connetics
shall be responsible for all freight, freight brokerage, insurance and other costs associated with shipping Genentech Finished Product hereunder. As soon as reasonably possible after each shipment of Genentech Finished Product, Genentech shall
forward to Connetics all customary documents concerning the shipment, including Genentech’s invoice relating to such shipment. To the extent possible, a certificate of analysis will be included in each shipment. Where it is not possible to
include a certificate of analysis with a shipment, Genentech shall furnish the same to Connetics as soon as reasonably possible. 

(c) Payment by Connetics shall be made within sixty (60) days after Connetics’ receipt of Genentech’s invoice
for the supply of Genentech Finished Product. All payments to Genentech by Connetics under this Agreement shall be made in United States dollars by wire transfer (or such other reasonable means as Genentech may direct) to such United States bank
account as Genentech may direct. If a wire transfer is to be made, Connetics shall provide notice at least five (5) days prior to the date of transfer of the amount of payment and the date good funds will be received. Such notice should be
given to the Treasurer of Genentech at the address set forth at the beginning of this Agreement or such other address as Genentech may subsequently direct. 

(d) Genentech shall use its best efforts to maintain its Fully Burdened Manufacturing Cost for Genentech Finished Product at or
below the benchmark costs of ***     dollars (***) per vial of Genentech Finished Product (the “Benchmark Costs”). All the provisions of Section 2.6(e) of that certain Supply Agreement, dated May 5, 1998,
between Genentech and Connetics, shall apply to such Benchmark Costs herein. 
 (e) All transfer of Genentech Finished
Product to Connetics or its sublicensee hereunder shall be subject to the provisions hereof and shall not be subject to the terms and conditions contained on any purchase order or confirmation by Genentech, except insofar as any such purchase order
or confirmation establishes: (i) the quantity and form of Genentech Product; (ii) the shipment date; (iii) the shipment routes and destinations; or (iv) the carrier. 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

7 

	13.	This Amendment supersedes in its entirety the Letter Agreement dated December 3, 1998. 

  

	14.	All other terms and provisions of the License Agreement, including all exhibits to that Agreement, will continue in full force and effect as though fully set forth in this Amendment. Nothing in this Amendment shall be
construed as affecting Connetics’ obligations to be liable and responsible for the performance of all of the obligations of Connetics and its sublicensees under the License Agreement. 

IN WITNESS WHEREOF, the parties have executed this Amendment Number Two to License Agreement as of the date first written above. 

 

									
	Genentech, Inc.				Connetics Corporation
					
	By: 		/s/ Nicholas J. Simon				By: 		/s/ Thomas G. Wiggans

									
	Name:		Nicholas J. Simon						Thomas G. Wiggans
	Title:		Vice President, Business and Corporate Development						President and Chief Executive Officer

 Acknowledged and agreed as to InterMune’s rights and obligations hereunder as Connetics’ sublicensee under the
License Agreement: 
  

			
	InterMune Pharmaceuticals, Inc.
		
	By:		/s/ Scott Harkonen
			Scott Harkonen, M.D.
			President

  
 8Ex-10.65

 Exhibit 10.65 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “***”. A COMPLETE VERSION OF THE EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT OF 1933. 

AMENDMENT NO. THREE 
 TO

 LICENSE AGREEMENT 

THIS AMENDMENT NUMBER THREE TO LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective April __, 1999
(the “Amendment Effective Date”), by and between Genentech, Inc. (“Genentech”) and Connetics Corporation (“Connetics”). Genentech and Connetics may each be referred to herein as a “Party” and jointly as the
“Parties.” 
 RECITALS 
  

	A.	The Parties have previously entered into that certain License Agreement for Interferon Gamma, dated May 5, 1998, as amended on December 23, 1998 and on January 15, 1999 (the “License
Agreement”). 

  

	B.	Pursuant to Section 2.3(c) of the License Agreement, Connetics has the right to sublicense certain of its rights under the Agreement to InterMune Pharmaceuticals, Inc. (“InterMune”), and has in fact
entered into such sublicense to that effect dated August 21, 1998. 

  

	C.	The Parties have entered into that certain letter agreement dated January 5, 1999 and revised on March 1, 1999 (the “Letter Agreement”), documenting the intent and agreement of Connetics and
Genentech with respect to certain additional rights to be granted to Connetics and its sublicensees under the Genentech License, pending the preparation of an amendment to the License Agreement. 

 

	D.	In consideration of such additional rights, ***
                                         
                                         
                                         
                         . 

  

	E.	The Parties now desire to enter into a definitive amendment to the License Agreement, as of the Amendment Effective Date, through which Genentech shall grant, and Connetics and InterMune shall accept, such certain
additional rights under the License Agreement. 

 NOW, THEREFORE, in consideration of the
foregoing and of the mutual covenants and conditions herein contained, and intending to be legally bound hereby, the Parties mutually agree as follows: 
  

	1.	Terms not otherwise defined in this Amendment shall have the meanings defined in the License Agreement. 

  

	2.	A new Section 1.7.1 is hereby added to read in its entirety as follows: 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

 1.7.1 “Combination Product Adjustment” shall mean the following: in the
event that a Licensed Product is sold in the form of a combination product containing one or more active ingredients or components in addition to such Licensed Product, Net Sales for such combination product will be adjusted by multiplying actual
Net Sales of such combination product by the fraction A/(A + B) where A is the invoice price of the Licensed Product, if sold separately, and B is the invoice price of any other active ingredient(s) or component(s) in the combination, if sold
separately. If, on a country-by-country basis, the other active ingredient(s) or component(s) in the combination are not sold separately in said country, Net Sales shall be calculated by multiplying actual Net Sales of such combination product by
the fraction A/C where A is the invoice price of the Licensed Product if sold separately, and C is the invoice price of the combination product. If, on a country-by-country basis, neither the Licensed Product nor the other active ingredient(s) or
component(s) of the combination product is sold separately in said country, Net Sales allocable to the Licensed Product shall be determined by mutual agreement reached in good faith by the Parties based on an equitable method of determining such Net
Sales that, among other considerations, takes into account, on a country-by-country basis, variations in potency, the relative contribution of each active ingredient or component in the combination product and the relative value to the end-user of
each active ingredient or component. 
  

	3.	Section 1.12 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

1.12 “Field of Use” shall mean the administration to humans of Licensed Protein Product for the treatment or
prevention of any human disease or condition, ***
                                         
               
                                         
                       
                    
                        
                                         
                                         
                      
                                    
                                 
                        
                                         
                                         
                      
                                    
                                          
                            . Each “indication” listed on Exhibit E attached hereto shall be
referred to herein individually as an “Area of the Field of Use” and collectively as “Areas of the Field of Use.” 
  

	4.	A new Section 1.15.1 is hereby added to the Agreement to read in its entirety as follows: 

1.15.1 “Gene Therapy Field of Use” shall mean the administration to humans of Licensed Gene Product for Gene Therapy
for the treatment or prevention of any human disease or condition, ***
                                         
                                         
                           
                                     
                                         
                                    
                . 
  

	5.	Section 1.18 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

1.18 “Genentech Patent Rights” shall mean all patents and patent applications and any patents issuing therefrom,
together with any extensions, reissues, reexaminations, substitutions, renewals, divisions, continuations and continuations-in-part thereof: 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

2 

 (a) that are owned or controlled by Genentech presently or hereafter, during the
term of this Agreement, and under which Genentech is free to license or sublicense; and 
 (b) to the extent they claim or
directly relate to: (i) Interferon Gamma or the manufacture or use of Interferon Gamma in the Field of Use, or (ii) IG Nucleotide Sequence or the manufacture or use of IG Nucleotide Sequence in the Gene Therapy Field of Use; 

including, without limitation, the patent rights granted under that certain license agreement between Genentech and Children’s Medical
Center Corporation, dated July 16, 1990 (the “CMCC License”), but specifically excluding any rights granted to Genentech under the Biogen License. Genentech Patent Rights shall include, without limitation, the patents and patent
applications listed in Exhibit A attached hereto. Notwithstanding the foregoing, Genentech Patent Rights shall exclude any rights Genentech acquires after the Effective Date under third-party license agreements, with the exception of those rights
acquired under the CMCC License, unless and until the Parties mutually agree on terms and conditions for the sublicense of such rights from Genentech to Connetics. 
  

	6.	A new Section 1.20.1 of the License Agreement is hereby added to read in its entirety as follows: 

1.20.1 “IG Nucleotide Sequence” shall mean any DNA or RNA sequence encoding Interferon Gamma. 

 

	7.	Section 1.22 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

1.22 “Licensed Product” shall mean, collectively: 

(a) Any pharmaceutical formulation containing Interferon Gamma, whether alone or together with or incorporated into any other
substance or product or material or device, whether active or not, and which (i) but for the licenses granted hereunder, the manufacture, use, sale, offer for sale or importation of which in the Territory would infringe or contribute to the
infringement of the Genentech Patent Rights in the Territory, or (ii) is based upon or incorporates or utilizes Genentech Knowhow (a “Licensed Protein Product”); and 

(b) Any pharmaceutical formulation containing the IG Nucleotide Sequence, whether alone or together with or incorporated into
any other substance or product or material or device, whether active or not, and which but for the licenses granted hereunder, the manufacture, use, sale, offer for sale or importation of which in the Territory would infringe or contribute to the
infringement of the Genentech Patent Rights in the Territory (a “Licensed Gene Product”). 
  

	8.	The following two sentences are hereby added to the end of Section 1.25: 

  
 3 

***                    
                                         
                                         
                                         
                                         
        
                                         
   
                                         
                                         
                                   
                                           
                                      
                                           
                                                
                                            , shall also be deducted from the
gross invoiced sales prices charged for such Licensed Products in determining Net Sales for such Licensed Products. In the event that a Licensed Product is sold in the form of a combination product containing one or more active ingredients or
components in addition to such Licensed Product, Net Sales for such combination product will be calculated in accordance with the Combination Product Adjustment.” 
  

	9.	Section 1.28 of the License Agreement is hereby deleted and replaced in its entirely as follows: 

1.28 “Territory” shall mean the United States of America, and its territories and possessions, and Japan. 

 

	10.	A new Section 1.37 is hereby added to the License Agreement to read in its entirety as follows: 

1.37 “Third Party Product Rights” shall mean any rights licensed or sublicensed to any third party by Genentech as of
the Effective Date to use, manufacture or sell (a) Interferon Gamma, (b) the IG Nucleotide Sequence or (c) any pharmaceutical formulation containing either or both of Interferon Gamma and the 1G Nucleotide Sequence, whether alone or
together with or incorporated into any other substance or product or material or device, whether active or not; ***
                                         
                                         
                                         
                             
                                    
                 
                                         
                      
                                    
                            . 
  

	11.	Section 2.1 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

2.1 Patent and Knowhow License Grants. 

(a) Genentech hereby grants to Connetics an exclusive license, even as to Genentech, under Genentech Patent Rights and under
Genentech Knowhow to use, sell, offer for sale and import (but not to make or have made) Licensed Protein Products in the Field of Use in the Territory (excluding Japan), (excluding, with respect to the fields of (i) scleroderma and
(ii) infectious disease or condition caused by human papillomavirus, Licensed Protein Products containing any form of Interferon Gamma other than Genentech Gamma Interferon D3 (as that term is
defined in the Biogen License)). Notwithstanding the foregoing, Genentech reserves the right to use (but not to import, offer for sale or sell) Licensed Protein Products within the Field of Use solely for noncommercial research purposes. 

(b) Genentech hereby grants to Connetics a non-exclusive license under Genentech Patent Rights and under Genentech Knowhow to
use, sell, offer for sale and import (but not to make or have made) Licensed Protein Products containing any form of Interferon Gamma other than Genentech Gamma 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

4 

 
Interferon D3 (as that term is defined in the Biogen License) in the Territory (excluding Japan) in the fields of: (i) scleroderma and
(ii) infectious disease or condition caused by human papillomavirus. 
 (c) Genentech hereby grants to Connetics a
non-exclusive sublicense under the Biogen License Rights to use, sell, offer for sale and import Licensed Protein Products (excluding Licensed Protein Products containing Biogen Gamma Interferon D0 (as
that term is defined in the Biogen License)) in the Territory (excluding Japan) in the fields of scleroderma and infectious disease or condition caused by human papillomavirus. 

(d) Genentech hereby, grants to Connetics a non-exclusive license under
Genentech Patent Rights to make or have made in the Territory (excluding Japan) Licensed Protein Products for use or sale in the Field of Use in the Territory (excluding Japan). 

(e) Genentech hereby grants to Connetics a non-exclusive license under Genentech Patent Rights and Genentech Knowhow to use
non-human animal species derived homologues of Interferon Gamma (“Non-human Interferon Gamma”) solely for non-commercial research purposes to support the Field of Use in the Territory (excluding Japan). Genentech hereby grants to Connetics
a non-exclusive license under Genentech Patent Rights to use non-human animal species derived homologues of IG Nucleotide Sequence (“Non-human Interferon Gamma-encoding IG Nucleotide Sequence”) solely for non-commercial research purposes
to support the Gene Therapy Field of Use in the Territory (excluding Japan). 
 (f) Genentech hereby grants to Connetics a
co-exclusive license under Genentech Patent Rights to use, make, have made, import, offer for sale and sell Licensed Gene Products in the Gene Therapy Field of Use in the Territory (excluding Japan). Notwithstanding the foregoing, Genentech reserves
the right to use (but not to import, offer for sale or sell) Licensed Gene Products within the Gene Therapy Field of Use solely for non-commercial research purposes. As used in this subsection (f), “co- exclusive” shall mean that
(i) Genentech shall not grant a license to any party other than Connetics to use, make, have made, import, offer for sale or sell Licensed Gene Products in the Gene Therapy Field in the Territory (excluding Japan) ***
                                         
                                         
                                         
                         , and (ii) Genentech shall not authorize or approve any grant or assignment ***
                                         
                                         
                                         
                                 . 

(g) (i) Genentech hereby grants to Connetics an exclusive license, even as to Genentech, under Genentech Patent Rights and
under Genentech Knowhow, in Japan to make, have made, use, sell, offer for sale and import
***                                         
   
                                         
                                
                            
                                          
                                         
                                      
                                         
                                             
                     

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

5 

 
                                
                                         
                                         
                           
                                      
            
                                         
                                         . 

(ii) Connetics, its Affiliates and sublicensees hereunder shall ***
                                         
                                         
      , to the extent based, in whole or in part, ***     
                                         
                                       
        
                                         
                       
                                         
                            
                                          
                                      
                                          
                                         
                                           
                                         
       
                                   
                                    for indications (including, without limitation, the
treatment of ***             
                                
                             
                                          
                     
                                         
                                    
                            
                            
                                      
                 
                                    
                                         
                                         
                                         
                                   
                                          
                               
                                         
                                         
                                         
                                       
                                           
                          
                                         
                                         
                  
                        
                                     
                              
                 . Connetics’ and its Affiliates’ and sublicensees’ ***              
                              
                                     shall terminate with respect to
***
                                         
                                         
                                         
                                         
                . 
 (iii) In the event that
any Third Party Product Rights held by a third party ***                          
                                           
                                         
                                         
                                         
     
                                         
                                         
                              revert to Genentech, then Genentech shall notify Connetics or its designated
sublicensee in Japan of such reversion, and upon such notice Genentech shall be deemed to have automatically granted to Connetics the license under Genentech Patent Rights and under Genentech Knowhow to all such reverted rights, which license shall
be exclusive to the extent that such reverted rights were exclusive. All rights granted to Connetics pursuant to this subsection (iii) shall be subject to the terms of this Agreement, including without limitation subsection (ii) above,
Section 3.2(g) and Section 8.3. 
 (h) In the event that any Third Party Product Rights (other than those described
in subsection (g) above) shall revert to Genentech, then Genentech shall notify Connetics of such reversion. For the ninety (90) day period following its receipt of such notice, Genentech and Connetics shall negotiate exclusively in good
faith the reasonable commercial terms upon which Genentech would be willing to grant to Connetics the license to such reverted rights. If the Parties fail to enter a written agreement for a license to such rights by the end of such ninety
(90) day period, then Genentech shall have no further obligation to Connetics with respect to such rights; provided that for six (6) months following such ninety 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

6 

 
(90) day period, Genentech shall not enter into an agreement to grant a license to such rights with a third party on terms that, taken as a whole, are less favorable to Genentech than those last
offered by Connetics for such rights. ***                      
                                         
                                         
                                         
                                     
                                      
                                     
                
                                         
                                    
                                          
                                      
                                 
                                         
                                    
                                          
                                      
                                 
                                         
                                    
                                          
                                        . Nothing in the preceding
sentence shall imply any ***
                                         
                                         
                              . Connetics may not transfer its rights under this Section 2.1(h)
to any party other than InterMune without Genentech’s prior written consent. 
 Except as expressly granted herein, there are no
implied licenses under the Genentech Patent Rights or any other intellectual property rights owned or controlled by Genentech. 
  

	12.	Section 2.3(b) of the License Agreement is hereby deleted and replaced in its entirety as follows: 

(b) Connetics may grant one or more sublicenses under the rights granted in Sections 2.1(a), (b), (c), (e), (f) and
(g) in the Field of Use and the Gene Therapy Field of Use, on thirty (30) days prior written notice to Genentech, and subject to Genentech’s prior written approval, which approval shall not be unreasonably withheld. 

 

	13.	A new Section 3.2(g) is hereby added to read in its entirely as follows: 

(g) In addition to the Clinical Development Milestones (as set forth in Exhibit E hereto), Connetics shall use its Best Efforts
to develop and commercialize Licensed Products: (i) in the Field of Use with respect to indications and diseases that, under the provisions of this Amendment, have been added to the “Field of Use” as defined in the original License
Agreement executed as of May 5, 1998, and (ii) in the Gene Therapy Field of Use. Such additional indications and diseases in the Field of Use, and the Gene Therapy Field of Use, collectively are referred to in this subsection (g) as
the “Additional Indications.” In the event that Connetics is not conducting such development efforts with respect to any Additional Indication(s) in a country or countries in the Territory as of the
***                                         
                                (or if rights to such Additional Indication were granted to
Connetics pursuant to Section 2.1(g)(iii), then as of the ***
                                that Genentech notifies Connetics or its designated
sublicensee regarding such rights as set forth in that Section) or at any time thereafter, Genentech shall have the right to terminate this Agreement, and the licenses granted hereunder, with respect to Licensed Products for such Additional
Indication(s) in such country or countries, upon             *** days prior written notice to Connetics, unless Connetics can reasonably 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

7 

 
demonstrate, during such notice period, by its written records that as of the date of such notice it is conducting such development efforts with respect to such Additional Indication(s) in such
country or countries. 
  

	14.	Sections 8.2(a) and (b) of the License Agreement are hereby deleted and replaced in their entirety as follows: 

(a)
***                                         
                                         
           within thirty (30) days following the dates on which the first NDA or BLA, as applicable, for a Licensed Protein Product is filed with the FDA by Connetics for ***
                                      
                                          
                                          
                                          
                                          
            ; provided however, that such milestone payments shall only be paid once for each of the foregoing indications, and shall not be paid upon the filing of a NDA or BLA for an
osteopetrosis or any mycobacterial infection indication. 
 (b)
***                                         
        within thirty (30) days following the date Connetics receives the first FDA approval of ***
                                         
                                         
                                         
                                      
                                   
                                         
                                         
                                         
                                   
                                        
                                         
                                         
                                        
                                         ; provided however, that
such milestone payment shall only be paid once for each of the foregoing indications, and shall not be paid upon receipt of FDA approval for commercial sale for an osteopetrosis or any mycobacterial infection indication. 

 

	15.	Section 8.3 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

8.3 Royalties. Connetics shall pay Genentech the following royalties on Net Sales of Licensed Products by Connetics and its
sublicensees: 
 (a) For annual aggregate Net Sales of all Licensed Protein Products in the Territory (excluding Japan) ***
                                         
                           , a royalty rate equal to
***                                         
    of such Net Sales. 
 (b)
***                                         
                                         
           , for annual aggregate Net Sales of all Licensed Protein Products in the Territory (excluding Japan) ***
                                         
                   , a royalty rate equal to
***                                         
                        of such Net Sales
***                                         
                                         
   . 
 (c) For Net Sales of all Licensed Protein Products in Japan, a royalty rate equal to
***                 of such Net Sales; provided, however, that in the event that ***
                                         
                                         
                              for an indication for which InterMune has exclusive rights under
Section 2.1(g), the foregoing royalty rate shall be reduced to
***                                         
                for Net Sales of
***                                         
        in Japan for such indication ***                            

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

8 

 
                                
                                         
                           . For the sake of clarity, Net Sales of Licensed Protein Products to which Connetics
acquires rights pursuant to Section 2.1(g)(iii) shall be subject to this subsection (c). 
 (d) (i) For Net Sales of
Licensed Gene Product in the Territory, where such Licensed Gene Product is used in conjunction with a Licensed Protein Product for the treatment or prevention of a given indication in a given patient population, a royalty rate equal to
***             of such Net Sales. As used in this subsection (d), “indication” shall mean any particular medical condition within the Field of Use and Gene Therapy Field of Use,
including but not limited to labeling claims approved by a regulatory agency. 
 (ii) For Net Sales of Licensed Gene Product
in a country in the Territory, where such Licensed Gene Product is used in a given patient population for the treatment or prevention of the same indication for which a given Licensed Protein Product is used in such patient population, a royalty
rate equal to (A) ***                     of such Net Sales during the
***                                         
        period following the first commercial sale of such Licensed Gene Product in such country for the treatment or prevention of such indication in such patient population by Connetics, or its Affiliates and
sublicensees (the “First Commercial Sale”);
(B) ***                                       
  of such Net Sales during the *** ***                                 period
following the First Commercial Sale; and (C) ***                     of such Net Sales beginning on the ***     anniversary
of the First Commercial Sale and thereafter. 
 (iii) Notwithstanding the provisions of subsections (i) and
(ii) above, in the event that annual Net Sales of a Licensed Gene Product for the treatment or prevention of an indication in a patient population in a country in the Territory
***                                         
                for the treatment or prevention of such indication in such patient population in such country, the royalty rate thereafter applicable to Net Sales of such
Licensed Gene Product for the treatment or prevention of such indication in such patient population in such country shall be ten percent (10%) of such Net Sales. 

(iv) In the event that Connetics or InterMune determines at any point following ***
                                         
                                         
          that the above royalty rates are having or are likely to have an adverse impact on Connetics’ or InterMune’s ability to compete effectively in its sales of such Licensed Gene
Product, Connetics or InterMune shall so notify Genentech, and the Parties shall in good faith discuss and attempt to reach a reasonable and mutually agreeable resolution to the situation. 

(e) (i) The royalties set forth in subsections (a), (b) and (c) above shall be payable, on a country-by-country
basis, until the later of: (A) the expiration or revocation of the last remaining issued patent in such country within the Genentech Patent Rights that covers Licensed Protein Products, or
(B) ***                     years from the Effective Date of this Agreement. Notwithstanding the

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

9 

 
foregoing, upon the expiration of the last to expire issued patent in each country within the Genentech Patent Rights during the term of this Agreement, thereafter each of the royalty rates set
forth in (a), (b) and (c) above shall be reduced by *** with respect to such country. 
 (ii) The royalties set
forth in subsection (d) above shall be payable, on a country-by-country basis, until the expiration or revocation of the last remaining issued patent in such country within the Genentech Patent Rights that covers Licensed Gene Products. 

 

	16.	Section 8.4 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

8.4 Third-Party Royalties. If Genentech or Connetics is required to pay any third party a royalty due to the manufacture, use,
sale, offer for sale or importation of a Licensed Product in the Territory for or by Connetics or its sublicensees, Connetics shall be responsible for the payment of ***
                                 of such third-party royalty, provided however,
that Connetics may deduct from the royalties otherwise payable to Genentech under Section 8.3 above, an amount equal to ***
                                 of such third party royalties incurred only due to use
patents in the Field of Use or in the Gene Therapy Field of Use in the Territory, provided that the amount deducted shall not exceed
***                                 of the royalties otherwise payable by Connetics to
Genentech under Section 8.3. For purposes of clarification, such deductions shall not apply to ***
                                         
                                         
          . Attached hereto as Exhibit G is a list of all such royalty obligations to third parties known to Genentech as of the Effective Date without diligent search. No later than thirty
(30) days from the Effective Date, Genentech shall complete a reasonable internal investigation of its records and update Exhibit G, as necessary, to accurately reflect all such royalty obligations to third parties to the best of
Genentech’s knowledge; provided however, Connetics acknowledges that Genentech has no obligation to conduct due diligence or any investigation with respect to third party patent rights related to Licensed Products. Genentech shall notify
Connetics in writing during the term of this Agreement if it becomes aware of any additional Genentech third party royalty obligations. 
  

	17.	Section 8.5 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

8.5 Royalty Payments. 

(a) Royalty payments shall be made to Genentech quarterly within ninety (90) days following the end of each calendar
quarter for which royalties are due. Each royalty payment shall be accompanied by a report summarizing the total Net Sales during the relevant three-month period, and the calculation of royalties, if any, due thereon pursuant to Section 8.3.

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

10 

 (b) Notwithstanding subsection (a) above, any royalty payments which accrue
during 1999 on Net Sales of Licensed Protein Product sold by Connetics’ sublicensee InterMune shall be paid to Genentech in the form of promissory note, in the form attached hereto as Exhibit I. For each calendar quarter in 1999 for which
royalty payments are due, InterMune shall execute and deliver to Genentech, within ninety (90) days following the end of each such calendar quarter, a promissory note in the form of Exhibit I, and in the amount of such royalties due to
Genentech for such quarter. Each such promissory note shall be accompanied by the report described in Section 8.5(a) above for such quarter. In the event that any such note is delivered by InterMune after such 90 day period, nevertheless
interest shall accrue on the date that such note was due. 
  

	18.	The following provision is hereby inserted as Section 10.4 to the License Agreement: 

10.4 Insurance. At all times during the term of this Agreement, Connetics and its sublicensees shall provide the following
insurance at its sole cost and expense: 
 (a) Commercial General Liability, including coverage for products and completed
operations (maintained for a period of at least ***                          after the expiration or termination of this
Agreement) ***                                            
                                        . The policy shall have a limit of no less than
***                                 dollars. 

(b) Foreign Local Coverages: Where required by law, Connetics and its sublicensees will purchase foreign local coverages in an
amount that, at a minimum, satisfies the legal requirements of that jurisdiction. 
 (c) Policy Conditions: All policies
under (a) and (b) above shall: 
 (i) be written by insurance companies with an A.M. Best’s rating of A:VIII
or higher (or if Connetics’ or its sublicensees policies are not subject to the Best rating, then by carriers who are acceptable to Genentech); and 

(ii) add Genentech as an additional insured. 

(d) Additionally, Connetics shall use its Best Efforts to obtain from its insurance carrier for the policies described in
subsections (a) and (b) covenants: 

(i)  ***                  
                                         
                                 
                                    
                                     
                                  
                                           
                                                    
             
                                 ; and 

(ii) ***
                                         
                                         
                                         
 
                                         
   
                                         
                                         
                                      
                                         
                               
                                
                            
                        
                                          
                                    
                
                            . 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

11 

	19.	Section 11.1 of the License Agreement is hereby deleted and replaced in its entirety as follows: 

11.1 Term. This Agreement shall commence on the Effective Date of this Agreement and, unless terminated earlier, shall expire:

 (a) With respect to Licensed Protein Products, at the later to occur of (i) the expiration of the last to expire of
any Genentech Patent Rights covering a Licensed Protein Product, or (ii) twenty (20) years from the Effective Date of this Agreement; and 

(b) With respect to Licensed Gene Products, at the expiration of the last to expire of any Genentech Patent Rights covering a
Licensed Gene Product; 
 provided, however, that in the event that either the CMCC License or the Biogen License is
terminated, the licenses granted by Genentech to Connetics under the CMCC License or the Biogen License shall also terminate. Genentech shall use its Best Efforts to keep the CMCC License and the Biogen License in effect during the term of this
Agreement, ***                                            
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
          . One (1) year before the expiration of this Agreement under Section 11.1(a), the Parties agree to meet and to discuss in good faith extending the term of this Agreement with respect to
Licensed Protein Products on terms mutually agreeable to the Parties. 
  

	20.	Exhibit E of the License Agreement is hereby deleted and replaced in its entirety with new Exhibit E attached hereto and incorporated herein. 

 

	21.	In consideration for the rights granted to Connetics and its sublicensees under this Amendment, ***                    
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
                             . 

  

	22.	This Amendment supersedes the Letter Agreement in its entirety. All other terms and provisions of the License Agreement, including all exhibits to that Agreement, will continue in full force and effect as though fully
set forth in this Amendment. Nothing in this Amendment shall be construed as affecting Connetics’ obligations to be liable and responsible for the performance of all of the obligations of Connetics and its sublicensees under the License
Agreement. 

 THIS SPACE INTENTIONALLY LEFT BLANK 

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

12 

 IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by the respective duly
authorized officers as of the date first written above. 
  

									
	GENENTECH, INC.				CONNETICS CORPORATION
					
	By: 		/s/ Nicholas J. Simon				By: 		/s/ Thomas G. Wiggans
	Printed Name: Nicholas J. Simon				Printed Name: Thomas G. Wiggans
	 Title: Vice President, Business and

          Corporate Development
				Title: President and Chief Executive Officer

 Acknowledged and agreed as to InterMune’s rights and obligations hereunder as Connetics’ sublicensee under the
License Agreement: 
  

			
	INTERMUNE PHARMACEUTICALS, INC.
		
	By: 		/s/ Scott Harkonen
	Printed Name: Scott Harkonen, M.D.
	Title: President

 Exhibit E 
  

													
					***						***		
			***										
													
									 ***
				
													
	 ***
				•  ***						***		
													
					•  ***						***		
					•  ***								
	 ***
				•  ***.						***		
					•  ***.								
					***:								
					***    						***		
					•  ***								
					•  ***								
					•  ***								
					-		***				***		
					-		***						
					***								
					•  ***						***		
					•  ***								
					•  ***						***		
	 ***
				•  ***						***		
					   ***						***		
					•  ***								
					•  ***						***		
					   ***								
	 ***
												

  

	***	Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. 

  

14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00240-of-00352.parquet"}]]